429 related articles for article (PubMed ID: 30865791)
1. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
Nunn AJ; Phillips PPJ; Meredith SK; Chiang CY; Conradie F; Dalai D; van Deun A; Dat PT; Lan N; Master I; Mebrahtu T; Meressa D; Moodliar R; Ngubane N; Sanders K; Squire SB; Torrea G; Tsogt B; Rusen ID;
N Engl J Med; 2019 Mar; 380(13):1201-1213. PubMed ID: 30865791
[TBL] [Abstract][Full Text] [Related]
2. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE; Nahid P; Kurbatova EV; Phillips PPJ; Bryant K; Dooley KE; Engle M; Goldberg SV; Phan HTT; Hakim J; Johnson JL; Lourens M; Martinson NA; Muzanyi G; Narunsky K; Nerette S; Nguyen NV; Pham TH; Pierre S; Purfield AE; Samaneka W; Savic RM; Sanne I; Scott NA; Shenje J; Sizemore E; Vernon A; Waja Z; Weiner M; Swindells S; Chaisson RE; ;
N Engl J Med; 2021 May; 384(18):1705-1718. PubMed ID: 33951360
[TBL] [Abstract][Full Text] [Related]
3. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Solodovnikova V; Liverko I; Moodliar R; Dodd M; Ngubane N; Rassool M; McHugh TD; Spigelman M; Moore DAJ; Ritmeijer K; du Cros P; Fielding K;
N Engl J Med; 2022 Dec; 387(25):2331-2343. PubMed ID: 36546625
[TBL] [Abstract][Full Text] [Related]
4. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
5. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
[TBL] [Abstract][Full Text] [Related]
6. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Gillespie SH; Crook AM; McHugh TD; Mendel CM; Meredith SK; Murray SR; Pappas F; Phillips PP; Nunn AJ;
N Engl J Med; 2014 Oct; 371(17):1577-87. PubMed ID: 25196020
[TBL] [Abstract][Full Text] [Related]
7. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
8. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI; Cousins C; Suresh C; Burhan E; Chew KL; Dalay VB; Lu Q; Kusmiati T; Balanag VM; Lee SL; Ruslami R; Pokharkar Y; Djaharuddin I; Sugiri JJR; Veto RS; Sekaggya-Wiltshire C; Avihingsanon A; Sarin R; Papineni P; Nunn AJ; Crook AM;
N Engl J Med; 2023 Mar; 388(10):873-887. PubMed ID: 36808186
[TBL] [Abstract][Full Text] [Related]
9. A four-month gatifloxacin-containing regimen for treating tuberculosis.
Merle CS; Fielding K; Sow OB; Gninafon M; Lo MB; Mthiyane T; Odhiambo J; Amukoye E; Bah B; Kassa F; N'Diaye A; Rustomjee R; de Jong BC; Horton J; Perronne C; Sismanidis C; Lapujade O; Olliaro PL; Lienhardt C;
N Engl J Med; 2014 Oct; 371(17):1588-98. PubMed ID: 25337748
[TBL] [Abstract][Full Text] [Related]
10. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
11. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.
Turkova A; Wills GH; Wobudeya E; Chabala C; Palmer M; Kinikar A; Hissar S; Choo L; Musoke P; Mulenga V; Mave V; Joseph B; LeBeau K; Thomason MJ; Mboizi RB; Kapasa M; van der Zalm MM; Raichur P; Bhavani PK; McIlleron H; Demers AM; Aarnoutse R; Love-Koh J; Seddon JA; Welch SB; Graham SM; Hesseling AC; Gibb DM; Crook AM;
N Engl J Med; 2022 Mar; 386(10):911-922. PubMed ID: 35263517
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
[TBL] [Abstract][Full Text] [Related]
13. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
[TBL] [Abstract][Full Text] [Related]
15. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.
Lienhardt C; Cook SV; Burgos M; Yorke-Edwards V; Rigouts L; Anyo G; Kim SJ; Jindani A; Enarson DA; Nunn AJ;
JAMA; 2011 Apr; 305(14):1415-23. PubMed ID: 21486974
[TBL] [Abstract][Full Text] [Related]
17. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
Nunn AJ; Rusen ID; Van Deun A; Torrea G; Phillips PP; Chiang CY; Squire SB; Madan J; Meredith SK
Trials; 2014 Sep; 15():353. PubMed ID: 25199531
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
[TBL] [Abstract][Full Text] [Related]
20. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
